-
公开(公告)号：US5807824A
公开(公告)日：1998-09-15
申请号：US463224
申请日：1995-06-05
IPC分类号： G01N33/566 , A61K38/00 , A61K39/395 , A61P1/00 , A61P1/16 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P19/06 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/04 , A61P37/06 , A61P43/00 , C07H21/04 , C07K14/47 , C07K16/18 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/19 , A61K38/16
CPC分类号： C07K14/472 , C07K16/18 , A61K38/00 , C07K2319/00
摘要： Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.
摘要翻译： 公开了人C5a的多肽类似物，其是显示基本上没有分泌毒素或激动剂活性的C5a受体拮抗剂，以及类似物的衍生物和类似物或衍生物的二聚体形式。 还提供了编码多肽的DNA分子和制备类似物的方法。 含有C5a类似物的药物制剂在治疗中用于治疗哺乳动物中C5a介导的疾病和炎性病症，并预防性地预防或减少由引起炎症或加重现有炎性病症的事件引起的炎症。 进一步公开的是对C5a类似物，其衍生物和类似物和衍生物的二聚体特异的抗体，其表现出与人C5a基本上没有交叉反应性。 所述抗体用于检测或定量循环C5a类似物或衍生物，以及修饰，例如中和体内C5a受体拮抗剂的活性。
-
2.发明授权DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same 失效编码具有基本上没有激动剂活性的C5A受体拮抗剂的DNA及其表达方法
公开(公告)号：US5837499A
公开(公告)日：1998-11-17
申请号：US463377
申请日：1995-06-05
IPC分类号： G01N33/566 , A61K38/00 , A61K39/395 , A61P1/00 , A61P1/16 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P19/06 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/04 , A61P37/06 , A61P43/00 , C07H21/04 , C07K14/47 , C07K16/18 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/19 , C12P21/00 , C07K14/435
CPC分类号： C07K14/472 , C07K16/18 , A61K38/00 , C07K2319/00
摘要： Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.
摘要翻译： 公开了人C5a的多肽类似物，其是显示基本上没有分泌毒素或激动剂活性的C5a受体拮抗剂，以及类似物的衍生物和类似物或衍生物的二聚体形式。 还提供了编码多肽的DNA分子和制备类似物的方法。 含有C5a类似物的药物制剂在治疗中用于治疗哺乳动物中C5a介导的疾病和炎性病症，并预防性地预防或减少由引起炎症或加重现有炎性病症的事件引起的炎症。 进一步公开的是对C5a类似物，其衍生物和类似物和衍生物的二聚体特异的抗体，其表现出与人C5a基本上没有交叉反应性。 所述抗体用于检测或定量循环C5a类似物或衍生物，以及修饰，例如中和体内C5a受体拮抗剂的活性。
-
搜索结果
2 条记录 (耗时 0.021 秒)
